These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29339393)

  • 1. Early Clinical Assessment of the Antimicrobial Activity of Finafloxacin Compared to Ciprofloxacin in Subsets of Microbiologically Characterized Isolates.
    Vente A; Bentley C; Lückermann M; Tambyah P; Dalhoff A
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29339393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections.
    Wagenlehner F; Nowicki M; Bentley C; Lückermann M; Wohlert S; Fischer C; Vente A; Naber K; Dalhoff A
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29339395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections.
    Dalhoff A; Schubert S; Vente A
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006.
    Peterson J; Kaul S; Khashab M; Fisher A; Kahn JB
    Clin Ther; 2007 Oct; 29(10):2215-21. PubMed ID: 18042477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics of Finafloxacin in Healthy Volunteers and Patients with Complicated Urinary Tract Infections.
    Taubert M; Lückermann M; Vente A; Dalhoff A; Fuhr U
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29339394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis.
    Connolly LE; Riddle V; Cebrik D; Armstrong ES; Miller LG
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis.
    Klausner HA; Brown P; Peterson J; Kaul S; Khashab M; Fisher AC; Kahn JB
    Curr Med Res Opin; 2007 Nov; 23(11):2637-45. PubMed ID: 17880755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis.
    Talan DA; Klimberg IW; Nicolle LE; Song J; Kowalsky SF; Church DA
    J Urol; 2004 Feb; 171(2 Pt 1):734-9. PubMed ID: 14713799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.
    Huntington JA; Sakoulas G; Umeh O; Cloutier DJ; Steenbergen JN; Bliss C; Goldstein EJ
    J Antimicrob Chemother; 2016 Jul; 71(7):2014-21. PubMed ID: 26994090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis.
    Peterson J; Kaul S; Khashab M; Fisher AC; Kahn JB
    Urology; 2008 Jan; 71(1):17-22. PubMed ID: 18242357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current issues in the management of urinary tract infections: extended-release ciprofloxacin as a novel treatment option.
    Blondeau JM
    Drugs; 2004; 64(6):611-28. PubMed ID: 15018591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis.
    Cox CE; Marbury TC; Pittman WG; Brown GL; Auerbach SM; Fox BC; Yang JY
    Clin Ther; 2002 Feb; 24(2):223-36. PubMed ID: 11911553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
    Arslan H; Azap OK; Ergönül O; Timurkaynak F;
    J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence of ESBL & Amp-C beta-lactamases & susceptibility to newer antimicrobial agents in complicated UTI.
    Taneja N; Rao P; Arora J; Dogra A
    Indian J Med Res; 2008 Jan; 127(1):85-8. PubMed ID: 18316858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets.
    Mendes RE; Castanheira M; Woosley LN; Stone GG; Bradford PA; Flamm RK
    Int J Antimicrob Agents; 2018 Aug; 52(2):287-292. PubMed ID: 29654893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary Tract Physiological Conditions Promote Ciprofloxacin Resistance in Low-Level-Quinolone-Resistant Escherichia coli.
    Martín-Gutiérrez G; Rodríguez-Beltrán J; Rodríguez-Martínez JM; Costas C; Aznar J; Pascual Á; Blázquez J
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4252-8. PubMed ID: 27139482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of Fluoroquinolone Resistance Score in Management of Complicated Urinary Tract Infections.
    Shah A; Justo JA; Bookstaver PB; Kohn J; Albrecht H; Al-Hasan MN
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of New Delhi metallo-β-lactamase 1 (NDM-1) producing and multidrug resistant uropathogens causing urinary tract infections in Andaman Islands, India.
    Bhattacharya D; Thamizhmani R; Bhattacharya H; Sayi DS; Muruganandam N; Roy S; Sugunan AP
    Microb Drug Resist; 2013 Dec; 19(6):457-62. PubMed ID: 23862639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Day versus 10-Day Course of Fluoroquinolones in Outpatient Males with a Urinary Tract Infection (UTI).
    Mospan GA; Wargo KA
    J Am Board Fam Med; 2016 Nov; 29(6):654-662. PubMed ID: 28076247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.